1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > A Competitive Analysis of the Global Breast Cancer Therapeutics Market : A New Class of Targeted Therapeutics Offers Novel Treatment Modalities to Treat Difficult Breast Cancers

Executive Summary

•The global breast cancer therapeutics market is divided into x segments: hormonal therapy, targeted therapy, chemotherapy, and other therapy (for example, novel drugs in development).
•About x hormonal therapies are available to treat breast cancer. The most common ones are aromatase inhibitors and selective oestrogen receptor modulators (SERMs).
•Only x approved targeted treatments are available in the U.S. market, namely, Herceptin (Roche) and Tykerb (GSK). 2 more drugs, Kadcyla (Roche) and Perjeta (Roche), were approved in 2013. At present, Roche dominates the global breast cancer therapeutics market.
•Although there are approximately x drugs indicated for the treatment of breast cancer, there remains a large unmet need to treat patients. As a result, the breast cancer pharmaceutical pipeline is strong, with about x drugs in development.
•Chemotherapy remains the most important class of drugs for breast cancer treatment; however, the trend of using targeted drugs is on the rise.
•Combination treatment is a focus for companies with breast cancer treatment in development; however, drugs that held potential in Phase 2 trials failed to make an impact in Phase 3, forcing companies to re-design trials or stop the research programme.
•Between 2015 and 2017, the key drugs to watch out for will be ABT-888 (AbbVie), NeuVax (Galena Biopharma), Palbociclib (Pfizer), NKTR-102 (Nektar), Nexavar (Bayer/Onyx), and CT-P6 (Celltrion).
•Palbocilib (Pfizer), LY2835219 (Eli Lilly), and LEE011(Novartis) are the most exciting drugs to look out for as they represent the cyclin-dependent kinases (CDK) unique class of drug inhibitors, a first of a kind from a breast cancer therapeutics perspective.
•Palbocilib is a CDK inhibitor oral drug that has been approved for filing and granted priority review by the U.S. Food and Drug Administration (FDA). If approved, this treatment will benefit patients as a first-line therapy (in combination with letrozole).
•LY2835219 (Eli Lilly) and LEE011 (Novartis) are the other key CDK inhibitors expected to compete with Palbocilib. Although no preliminary data is available in terms of Phase 3 trials, at present, they are anticipated with positive enthusiasm from their developers.
•In 2014, market size was estimated at $ x billion; the market is expected to witness a compound annual growth rate (CAGR) of x % over the next x years.

Physician Guidelines to Breast Cancer Therapy—Her 2 Positive

•Herceptin therapy, along with chemotherapy combination, such as Xeloda and Tykerb, represents the standard treatment regime for Her 2-positive breast cancer.
•This standard treatment is also being administered subcutaneously to reduce run time. Most breast cancer patients benefit from this therapy, demonstrating an affirmative response to Her 2 positive.
•New versions, such as Kadcyla and Perjeta, leverage Roche’s proprietary technology.

Physician Guidelines to Breast Cancer Therapy—ER or PR Positive

•Hormone-positive patients represent the next largest market and are usually treated with Faslodex, along with chemotherapeutic agents, such as anthracyclines or taxanes.
• Exemestane is usually prescribed after the failure of Tamoxifen. It also serves as a third-line therapy option for advanced breast cancer patients.

Physician Guidelines to Breast Cancer Therapy— Triple-negative Breast Cancer

•Ideally, anthracyclin or taxane is administered to patients with triple-negative breast cancer as they do not respond to either hormone therapy or Her 2-positive-targeted therapeutics.
•At present, new and promising therapeutic targets, such as CDKs, poly-adenosine ribose phosphates, and epidermal growth factor receptors are being evaluated to develop drugs to fulfil this unmet need.

Table Of Contents

A Competitive Analysis of the Global Breast Cancer Therapeutics Market : A New Class of Targeted Therapeutics Offers Novel Treatment Modalities to Treat Difficult Breast Cancers
Executive Summary 6
Physician Guidelines to Breast Cancer Therapy—Her 2 Positive 9
Physician Guidelines to Breast Cancer Therapy—ER or PR Positive 10
Physician Guidelines to Breast Cancer Therapy—Triple-negative Breast Cancer 11
Key Trends 12
Market Opportunities 13
Companies to Watch 14
Methodology and Scope 15
Market Overview 17
Market Overview—Introduction 18
Market Overview—Incidence Rate of Breast Cancer 20
Market Size 21
Market Segmentation 22
Competitive Landscape—Breast Cancer Marketed Products and Pipeline Candidates 23
Competitive Landscape Overview 24
Competitive Landscape—Breast Cancer Marketed and Pipeline Products 25
Marketed Products—Hormone Therapy 26
Pipeline Products—Hormone Therapy 28
Marketed Products—Targeted Therapy 29
Pipeline Products—Targeted Therapy 30
Marketed Products—-Chemotherapy 32
Pipeline Products—Chemotherapy 34
Pipeline Products—Other Therapies 35
Product Launch Timeline 36
Patent Expirations 37
Pivotal Phase 3 Trials 38
Breast Cancer Therapeutics—Major Ongoing/Recently Completed Clinical Trials 39
Summary of Key Products to Watch 42
Product Dashboard (Marketed Products and Phase 3 Candidates) 43
Product Dashboard—Herceptin (Trastuzumab) 44
Product Dashboard—Afinitor (Everolimus) 45
Product Dashboard—Arimidex (Anastrozole) 46
Product Dashboard—Perjeta (Pertuzumab) 47
Product Dashboard—Tykerb (Lapatinib) 48
Product Dashboard—Taxol (Paclitaxel) 49
Product Dashboard—Xeloda (Capecitabine) 50
Product Dashboard—Kadcyla (Ado-trastuzumab emtansine) 51
Product Dashboard—PD-0332991(Palbociclib) 52
Product Dashboard—NeuVax (Nelipepimut-S) 53
Conclusions 54
Appendix 57
The Frost and Sullivan Story 61

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8 085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8 085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Infectious Disease Statistics and Therapy Market in the US

  • October 2016
    77 pages
  • Infectious Dise...  



  • United States  

View report >

Therapy Market in the US - Forecast

  • October 2016
    6 pages
  • Therapy  


  • United States  

View report >

Ovarian Cancer Statistics in the UK

  • October 2016
    39 pages
  • Ovarian Cancer  



  • United Kingdom  


View report >

Therapy Market

8 days ago

Therapy Market

8 days ago

Related Market Segments :

Breast Cancer


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.